Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 11, 2022 17:30 ET | Source: ProKidney

ProKidney Corp. Reports Second Quarter 2022 Financial Results and Provides Business Update

WINSTON-SALEM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (formerly Social Capital Suvretta Holdings Corp. III or “SCS”) (Nasdaq: PROK) (the “Company”), a leading late clinical-stage...
August 11, 2022 10:01 ET | Source: ProKidney

ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox

Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney Fox joins Board with more than 25 years of healthcare...
July 20, 2022 08:00 ET | Source: ProKidney

ProKidney Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs

WINSTON-SALEM, NC, July 20, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on Chronic...
July 12, 2022 08:00 ET | Source: ProKidney

Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to List on the Nasdaq Following Business Combination with Social Capital Suvretta Holdings Corp. III

ProKidney Class A ordinary shares to begin trading on Nasdaq under the ticker symbol “PROK” on July 12, 2022 ProKidney receives total gross proceeds of approximately $597 million, expected to fund...
June 23, 2022 08:00 ET | Source: ProKidney

ProKidney Corroborates the Mechanism of Action of REACT™ with Cell Marker Analysis in Patients with Diabetic Chronic Kidney Disease

WINSTON-SALEM, N.C., June 23, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and...
June 15, 2022 08:00 ET | Source: ProKidney

ProKidney Announces Manufacturing Efficiency Initiatives and Supply Chain Streamlining Expected to Reduce REACT™ Manufacturing Costs

WINSTON-SALEM, N.C., June 15, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (“ProKidney”), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (“CKD”),...
June 07, 2022 08:00 ET | Source: ProKidney

Observed Safety Profile Supports Bilateral Dosing of ProKidney’s REACT™ – 007 Update

Potential for Amplified Therapeutic Effect of REACT™ with Bilateral Kidney Injections Potential to report data from enhanced delivery approach 1Q 2023 WINSTON-SALEM, N.C., June 07, 2022 (GLOBE...
May 20, 2022 09:00 ET | Source: ProKidney

ProKidney to present at upcoming investor conferences

WINSTON-SALEM, N.C., May 20, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and...
May 03, 2022 08:00 ET | Source: ProKidney

ProKidney highlights key registrational program elements supporting advancement of REACT®

WINSTON-SALEM, N.C., May 03, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and...
April 28, 2022 08:00 ET | Source: ProKidney

ProKidney Appoints Libbie Parker McKenzie, MD, FASN as Chief Medical Officer

WINSTON-SALEM, N.C., April 28, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and...